[ @entity1363 treatment for @entity159 of XXXX ].

@entity1 @entity410 @entity198 @entity75 @entity519 @entity2146 @entity302 @entity1363 @entity159
We investigated the efficacy and safety of @entity1363 given intravenously for the treatment of @entity159 in @entity1 . @entity1 received one to three bolus injections of @entity1363 (0.15 to 0.40 mg/kg) until @entity410 disappeared completely. In other @entity1 , continuous infusion of @entity1363 (0.06 to 0.48 mg/kg/hr) followed a bolus of @entity1363 or other anti- @entity302 agents. The dose was increased every 15 minutes until the @entity410 were brought under control. The etiology of 62 episodes of @entity159 was @entity302 in 43, acute @entity75 / @entity198 in 11, @entity410 in 7 and hypoxic @entity75 in 1. The age of the @entity1 ranged from 0.2 to 18.4 years (average: 3.7 years). Bolus injections were administered in 53 episodes. The average loading dose was 0.35 +/- 0.22 mg/kg (range 0.15 to 0.90 mg/kg). Of the 42 episodes in which @entity410 disappeared, 13 required no further continuous infusions. Of the remaining 29 in which continuous infusion was done at the rate of 0.06 to 0.60 mg/kg/hr (mean 0.30 mg/kg/hr), 21 ended in cessation of the @entity410 . The duration of continuous infusions ranged from 4 to 288 hours (average 49.0 hours). In 6 episodes there were adverse effects:transient @entity519 (5) and @entity2146 during withdrawal (1). No intervention was needed except oxygenation by mask for less than 72 hours. @entity1363 is effective and safe, and can be used as the first line drug in the treatment of @entity159 in @entity1 .
